Although Liang Y et al reported potent in vivo anti-tumor efficacy of the anti-PD-L1-mIFN-α fusion, the IFNR downstream pathways in the tumor cells that mediated the anti-tumor efficacy were not fully investigated. This evidence concerns the gene IFNAR2 and neoplasm.